| 74.33 -3.37 (-4.34%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 99.48 |
1-year : | 109.33 |
| Resists | First : | 85.17 |
Second : | 93.61 |
| Pivot price | 83.67  |
|||
| Supports | First : | 71.52 |
Second : | 59.51 |
| MAs | MA(5) : | 75.47 |
MA(20) : | 84.43 |
| MA(100) : | 62.52 |
MA(250) : | 43.78 |
|
| MACD | MACD : | -0.5 |
Signal : | 1.6 |
| %K %D | K(14,3) : | 17.9 |
D(3) : | 12.7 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 93.61 | Low : | 21.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LQDA ] has closed above bottom band by 12.6%. Bollinger Bands are 74.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 76.48 - 76.92 | 76.92 - 77.32 |
| Low: | 71.85 - 72.31 | 72.31 - 72.73 |
| Close: | 73.65 - 74.41 | 74.41 - 75.09 |
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Tue, 18 Aug 2026
Handelsbanken Fonder AB Invests $1.99 Million in Liquidia Corporation $LQDA - MarketBeat
Mon, 17 Aug 2026
A Look at Liquidia Corp (LQDA) After 4.3% Gain -- GF Value $267. - GuruFocus
Mon, 17 Aug 2026
Liquidia (NASDAQ: LQDA) affiliate plans new stock sale after $710K July trade - Stock Titan
Mon, 17 Aug 2026
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now? - TradingView
Mon, 17 Aug 2026
Greenhaven Road Capital: Short Term Gain Realized from Liquidia (LQDA), Investment to Be Revisited - Yahoo Finance
Sun, 16 Aug 2026
Liquidia (LQDA) Is Down 17.5% After Swinging To Q2 Profitability On Surging Revenue - Has The Bull Case Changed? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 0 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 6.248e+007 (%) |
| Held by Institutions | 12.6 (%) |
| Shares Short | 11,610 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 4.663e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 7.7 % |
| Operating Margin | 46.2 % |
| Return on Assets (ttm) | 9 % |
| Return on Equity (ttm) | 28.1 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 278.07 |
| Sales Per Share | 5.05368e+008 |
| EBITDA (p.s.) | 4.64018e+008 |
| Qtrly Earnings Growth | 0.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 48 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 34.44 |
| Dividend | 0 |
| Forward Dividend | 1.233e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|